Toward a cancer-specific diet

Clinical Nutrition

Volumn 35, Issue 5, 2016, Pages 1188-1195

  Bozzetti, Federico ^a   Zupec Kania, Beth ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b The Charlie Foundation   (United States)

Author keywords

Calorie restriction and tumour growth; Dietary manipulation and tumour growth; Fat enriched diet; High fat carbohydrate ratio; Ketogenic diet; Nutritional support and tumour growth

Indexed keywords

6 PHOSPHOFRUCTOKINASE; ADENOSINE TRIPHOSPHATE; HEXOKINASE 1; HYDRAZINE SULFATE; SOMATOMEDIN BINDING PROTEIN 1; KETONE BODY; TRIACYLGLYCEROL;

ARTICLE; BIOAVAILABILITY; BIOSYNTHESIS; BODY MASS; BODY WEIGHT; CALORIC RESTRICTION; CANCER SURVIVAL; CELL RENEWAL; DIET THERAPY; ENERGY CONSUMPTION; ENERGY METABOLISM; ENZYME ACTIVATION; ENZYME ACTIVITY; FATTY ACID OXIDATION; GASTROINTESTINAL CARCINOMA; GLUCOSE METABOLISM; GLYCOLYSIS; HETEROZYGOSITY; HUMAN; KETOGENIC DIET; LIPOLYSIS; LUNG CANCER; MALNUTRITION; MITOGENESIS; NEOPLASM; NEUROBLASTOMA; NONHUMAN; NUTRITIONAL ASSESSMENT; NUTRITIONAL SUPPORT; OXIDATION; OXIDATIVE PHOSPHORYLATION; PROTEIN METABOLISM; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; TUMOR GROWTH; ADMINISTRATION AND DOSAGE; ANIMAL; DISEASE MODEL; FAT INTAKE; METABOLISM; NUTRITIONAL REQUIREMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); TUMOR CELL LINE;

ANIMALS; CALORIC RESTRICTION; CELL LINE, TUMOR; DIET, KETOGENIC; DIETARY FATS; DISEASE MODELS, ANIMAL; ENERGY METABOLISM; HUMANS; KETONE BODIES; NEOPLASMS; NUTRITIONAL REQUIREMENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRIGLYCERIDES;

EID: 84923163846     PISSN: 02615614     EISSN: 15321983     Source Type: Journal    
DOI: 10.1016/j.clnu.2015.01.013     Document Type: Article

References (158)

1. [1] Schwartz, G.F., Green, H.L., Bendon, M.L., Graham, W.P. 3rd, Blakemore, W.S., Combined parenteral hyperalimentation and chemotherapy in the treatment of disseminated solid tumors. Am J Surg 121:2 (1971 Feb), 169–173.
2. [2] Bozzetti, F., Nutritional support in oncologic patients: where we are and where we are going. Clin Nutr 30:6 (2011 Dec), 714–717.
3. [3] Warburg, O., Wind, F., Negelein, E., The metabolism of tumors in the body. J Gen Physiol 8 (1927), 519–530.
4. [4] Hoskin, P.J., Sibtain, A., Daley, F.M., Wilson, G.D., GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Br J Cancer 89 (2003), 1290–1297.
5. [5] Lambert, D.W., Wood, I.S., Ellis, A., Shirazi-Beechey, S.P., Molecular changes in the expression of human colonic nutrient transporters during the transition from normality to malignancy. Br J Cancer 86 (2002), 1262–1269.
6. [6] Yamamoto, T., Seino, Y., Fukumoto, H., Koh, G., Yano, H., Inagaki, N., et al. Overexpression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun 170 (1990), 223–230.
7. [7] Mathupala, S.P., Ko, Y.H., Pedersen, P.L., Hexokinase-2 bound to mitochondria: cancer's stygian link to the “Warburg effect” and a pivotal target for effective therapy. Semin Cancer Biol 19 (2009), 17–24.
8. [8] Mathupala, S.P., Rempel, A., Pedersen, P.L., Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem 276 (2001), 43407–43412.
9. [9] Moreno-Sánchez, R., Rodríguez-Enríquez, S., Marín-Hernández, A., Saavedra, E., Energy metabolism in tumor cells. FEBS J 274 (2007), 1393–1418.
10. [10] Deberardinis, R.J., Sayed, N., Ditsworth, D., Thompson, C.B., Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 18 (2008), 54–61.
11. [11] Flier, J.S., Mueckler, M.M., Usher, P., Lodish, H.F., Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 235:4795 (1987), 1492–1495.
12. [12] Barthel, A., Okino, S.T., Liao, J., Nakatani, K., Li, J., Whitlock, J.P. Jr., et al. Regulation of GLUT1 gene transcription by the serine/threonine kinase Akt1. J Biol Chem 274:29 (1999), 20281–20286.
13. [13] Kohn, A.D., Summers, S.A., Birnbaum, M.J., Roth, R.A., Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. J Biol Chem 271:49 (1996), 31372–31378.
14. [14] Cairns, R.A., Harris, I.S., Mak, T.W., Regulation of cancer cell metabolism. Nat Rev Cancer 11:2 (2011), 85–95.
15. [15] Gottlob, K., Majewski, N., Kennedy, S., Kandel, E., Robey, R.B., Hay, N., Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev 15:11 (2001), 1406–1418.
16. [16] Deprez, J., Vertommen, D., Alessi, D.R., Hue, L., Rider, M.H., Phosphorylation and activation of heart 6-phosphofructo-2-kinase by protein kinase B and other protein kinases of the insulin signaling cascades. J Biol Chem 272:28 (1997), 17269–17275.
17. [17] David, C.J., Chen, M., Assanah, M., Canoll, P., Manley, J.L., HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463:7279 (2010), 364–368.
18. [18] Luo, W., Semenza, G.L., Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells. Oncotarget 2:7 (2011), 551–556.
19. [19] Cantor, J.R., Sabatini, D.M., Cancer cell metabolism: one hallmark, many faces. Cancer Discov 2:10 (2012), 881–898.
20. [20] Burt, M.E., Norton, J.A., Brennan, M.F., The human tumor-bearing limb: an ex vivo model. Surgery 87:2 (1980; Feb), 128–132.
21. [21] Norton, J.A., Burt, M.E., Brennan, M.F., In vivo utilization of substrate by human sarcoma-bearing limbs. Cancer 45:12 (1980 Jun 15), 2934–2939.
22. [22] Greschner, M., Saeger, H.D., Barth, H., Leweling, H., Holm, E., Balances of energy-yielding substrates across malignant gastric tumours in man. Clin Nutr, 10(Suppl.), 1991, 12.
23. [23] Hagmüller, E., Kollmar, H.B., Günther, H.J., Holm, E., Trede, M., Protein metabolism in human colon carcinomas: in vivo investigations using a modified tracer technique with L-[1-13C]leucine. Cancer Res 55:5 (1995 Mar 1), 1160–1167.
24. [24] Holm, E., Hagmüller, E., Staedt, U., Schlickeiser, G., Günther, H.J., Leweling, H., et al. Substrate balances across colonic carcinomas in humans. Cancer Res 55:6 (1995 Mar 15), 1373–1378.
25. [25] van der Hulst, R.R., von Meyenfeldt, M.F., Deutz, N.E., Soeters, P.B., Glutamine extraction by the gut is reduced in depleted [corrected] patients with gastrointestinal cancer. Ann Surg 225:1 (1997 Jan), 112–121.
26. [26] Wise, D., DeBerardinis, R., Mancuso, A., Sayeda, N., Zhang, X., Pfeiffer, H., et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. PNAS 105 (2008), 18782–18787.
27. [27] Lieberman, B.P., Ploessl, K., Wang, L., Qu, W., Zha, Z., Wise, D.R., et al. PET imaging of glutaminolysis in tumors by 18F-(2S,4R)4-fluoroglutamine. J Nucl Med 52:12 (2011), 1947–1955.
28. [28] Potts, R., Humanity's descent: the consequences of ecological instability. 1996, William Morrow, New York, NY.
29. [29] Seyfried, T.N., Cancer as a metabolic disease: on the origin, management, and prevention of cancer. 2012, John Wiley, Hoboken, NJ.
30. [30] Seyfried, T.N., Shelton, L.M., Mukherjee, P., Does the existing standard of care increase glioblastoma energy metabolism?. Lancet Oncol 11:9 (2010 Sep), 811–813.
31. [31] Nolop, K.B., Rhodes, C.G., Brudin, L.H., Beaney, R.P., Krausz, T., Jones, T., et al. Glucose utilization in vivo by human pulmonary neoplasms. Cancer 60:11 (1987 Dec 1), 2682–2689.
32. [32] Rous, P., The influence of diet on transplanted and spontaneous mouse tumors. J Exp Med 20 (1914), 433–451.
33. [33] Mukherjee, P., El-Abbadi, M.M., Kasperzyk, J.L., Ranes, M.K., Seyfried, T.N., Dietary restriction reduces angiogenesis and growth in an orthotopic mouse brain tumour model. Br J Cancer 86 (2002), 1615–1621.
34. [34] Mukherjee, P., Abate, L.E., Seyfried, T.N., Antiangiogenic and proapoptotic effects of dietary restriction on experimental mouse and human brain tumors. Clin Cancer Res 10 (2004), 5622–5629.
35. [35] Yang, C., Sudderth, J., Dang, T., Bachoo, R.G., McDonald, J.G., DeBerardinis, R.J., Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res 69 (2009), 7986–7989.
36. [36] Shelton, L.M., Huysentruyt, L.C., Mukherjee, P., Seyfried, T.N., Calorie restriction as an anti-invasive therapy for malignant brain cancer in the VM mouse. ASN Neuro, 2, 2010, e00038.
37. [37] Mukherjee, P., Sotnikov, A.V., Mangian, H.J., Zhou, J.R., Visek, W.J., Clinton, S.K., Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression. J Natl Cancer Inst 91 (1999), 512–523.
38. [38] De Lorenzo, M.S., Baljinnyam, E., Vatner, D.E., Abarzua, P., Vatner, S.F., Rabson, A.B., Caloric restriction reduces growth of mammary tumors and metastases. Carcinogenesis 32 (2011), 1381–1387.
39. [39] Phoenix, K.N., Vumbaca, F., Fox, M.M., Evans, R., Claffey, K.P., Dietary energy availability affects primary and metastatic breast cancer and metformin efficacy. Breast Cancer Res Treat 123 (2010), 333–344.
40. [40] Thompson, H.J., McGinley, J.N., Spoelstra, N.S., Jiang, W., Zhu, Z., Wolfe, P., Effect of dietary energy restriction on vascular density during mammary carcinogenesis. Cancer Res 64 (2004), 5643–5650.
41. [41] Veech, R.L., The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostagl Leukot Essent Fat Acids 70:3 (2004 Mar), 309–319.
42. [42] Cullingford, T.E., The ketogenic diet; fatty acids, fatty acid activated receptors and neurological disorders. Prostagl Leukot Essent Fat Acids 70 (2004), 253–264.
43. [43] Leino, R.L., Gerhart, D.Z., Duelli, R., Enerson, B.E., Drewes, L.R., Diet-induced ketosis increases monocarboxylate transporter (MCT1) levels in rat brain. Neurochem Int 38 (2001), 519–527.
44. [44] Nehlig, A., Brain uptake and metabolism of ketone bodies in animal models. Prostagl Leukot Essent Fat Acids 70 (2004), 265–275.
45. [45] Veech, R.L., The determination of the redox states and phosphorylation potential in living tissues and their relationship to metabolic control of disease phenotypes. Biochem Mol Biol Educ 34:3 (2006 May), 168–179.
46. [46] Tisdale, M.J., Brennan, R.A., Loss of acetoacetate coenzyme A transferase activity in tumours of peripheral tissues. Br J Cancer 47 (1983), 293–297.
47. [47] Skinner, R., Trujillo, A., Ma, X., Beierle, E.A., Ketone bodies inhibit the viability of human neuroblastoma cells. J Pediatr Surg 44:1 (2009 Jan), 212–216.
48. [48] Maurer, G.D., Brucker, D.P., Bähr, O., Harter, P.N., Hattingen, E., Walenta, S., et al. Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy. BMC Cancer, 11, 2011 Jul 26, 315, 10.1186/1471-2407-11-315.
49. [49] Chang, H.T., Olson, L.K., Schwartz, K.A., Ketolytic and glycolytic enzymatic expression profiles in malignant gliomas: implication for ketogenic diet therapy. Nutr Metab, 10, 2013, 47, 10.1186/1743-7075-10-47.
50. [50] Fine, E.J., Miller, A., Quadros, E.V., Sequeira, J.M., Feinman, R.D., Acetoacetate reduces growth and ATP concentration in cancer cell lines which over-express uncoupling protein 2. Cancer Cell Int, 9, 2009 May 29, 14, 10.1186/1475-2867-9-14.
51. [51] Marie, S.K., Shinjo, S.M., Metabolism and brain cancer. Clinics – Sao Paulo 66:Suppl. 1 (2011), 33–43.
52. [52] Puzio-Kuter, A.M., The role of p53 in metabolic regulation. Genes Cancer 2 (2011), 385–391.
53. [53] Jiang, Y.S., Wang, F.R., Caloric restriction reduces edema and prolongs survival in a mouse glioma model. J Neurooncol 214 (2013), 25–32.
54. 2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation. Biochem J 418 (2009), 29–37.
55. [55] Allen, B.G., Bhatia, S.K., Buatti, J.M., Brandt, K.E., Lindholm, K.E., Button, A.M., et al. Ketogenic diets enhance oxidative stress and radio-chemo-therapy responses in lung cancer xenografts. Clin Cancer Res 19:14 (2013), 3905–3913.
56. [56] Rajaram, S., Baylink, D.J., Mohan, S., Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 18 (1997), 801–831.
57. [57] Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
58. [58] Lewis, K.N., Mele, J., Hayes, J.D., Buffenstein, R., Nrf2, a guardian of health span and gatekeeper of species longevity. Integr Comp Biol 50:5 (2010 Nov), 829–843.
59. [59] Sinclair, D.A., Toward a unified theory of caloric restriction and longevity regulation. Mech Ageing Dev 126:9 (2005 Sep), 987–1002.
60. [60] Raffaghello, L., Lee, C., Safdie, F.M., Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc Natl Acad Sci U. S. A 105 (2008), 8215–8220.
61. [61] Lee, C., Safdie, F.M., Raffaghello, L., Wei, M., Madia, F., Parrella, E., et al. Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index. Cancer Res 2010:70 (2010), 1564–1572.
62. [62] Lee, C., Raffaghello, L., Brandhorst, S., Safdie, F.M., Bianchi, G., Martin-Montalvo, A., et al. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med 4:124 (2012 Mar 7), 124–127.
63. [63] Safdie, F., Brandhorst, S., Wei, M., Wang, W., Lee, C., Hwang, S., et al. Fasting enhances the response of glioma to chemo- and radiotherapy. PLoS One, 7(9), 2012, e44603, 10.1371/journal.pone.0044603 [Epub 2012 Sep 11].
64. [64] Thissen, J.P., Ketelslegers, J.M., Underwood, L.E., Nutritional regulation of the insulin-like growth factors. Endocr Rev 15 (1994), 80–101.
65. [65] Spindler, S.R., Dhahbi, J.M., Conserved and tissue-specific genic and physiologic responses to caloric restriction and altered IGFI signaling in mitotic and postmitotic tissues. Annu Rev Nutr 27 (2007), 193–217.
66. [66] Mote, P.L., Tillman, J.B., Spindler, S.R., Glucose regulation of GRP78 gene expression. Mech Ageing Dev 104 (1998), 149–158.
67. [67] Reddy, R.K., Mao, C., Baumeister, P., Austin, R.C., Kaufman, R.J., Lee, A.S., Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation. J Biol Chem 278 (2003), 20915–20924.
68. [68] Fontana, L., Klein, S., Aging, adiposity, and calorie restriction. JAMA 297 (2007), 986–994.
69. [69] Blagosklonny, M.V., Pardee, A.B., Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res 61 (2001), 4301–4305.
70. [70] Anzo, M., Cobb, L.J., Hwang, D.L., Mehta, H., Said, J.W., Yakar, S., et al. Targeted deletion of hepatic Igf1 in TRAMP mice leads to dramatic alterations in the circulating insulin-like growth factor axis but does not reduce tumor progression. Cancer Res 68:9 (2008 May 1), 3342–3349.
71. [71] Holzenberger, M., Dupont, J., Ducos, B., IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature 421 (2003), 182–187.
72. [72] Blagosklonny, M.V., Darzynkiewicz, Z., Cyclotherapy: protection of normal cells and unshielding of cancer cells. Cell Cycle 1 (2002), 375–382.
73. [73] Shi, Y., Felley-Bosco, E., Marti, T.M., Orlowski, K., Pruschy, M., Stahel, R.A., Starvation-induced activation of ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatin. BMC Cancer, 12, 2012 Dec 4, 571.
74. [74] Brandhorst, S., Wei, M., Hwang, S., Morgan, T.E., Longo, V.D., Short-term calorie and protein restriction provide partial protection from chemotoxicity but do not delay glioma progression. Exp Gerontol 48:10 (2013 Oct), 1120–1128.
75. [75] Seyfried, T.N., Marsh, J., Shelton, L.M., Huysentruyt, L.C., Mukherjee, P., Is the restricted ketogenic diet a viable alternative to the standard of care for managing malignant brain cancer?. Epilepsy Res 100:3 (2012), 310–326.
76. [76] Seyfried, T.N., Sanderson, T.M., El-Abbadi, M.M., McGowan, R., Mukherjee, P., Role of glucose and ketone bodies in the metabolic control of experimental brain cancer. Br J Cancer 89:7 (2003 Oct 6), 1375–1382.
77. [77] Marsh, J., Mukherjee, P., Seyfried, T.N., Akt-dependent proapoptotic effects of dietary restriction on late-stage management of a phosphatase and tensin homologue/tuberous sclerosis complex 2-deficient mouse astrocytoma. Clin Cancer Res 14:23 (2008 Dec 1), 7751–7762.
78. [78] Seyfried, T.N., Shelton, L.M., Cancer as a metabolic disease. Nutr Metab – Lond, 7, 2010 Jan 27, 7, 10.1186/1743-7075-7-7.PMID 20181022.
79. [79] Seyfried, T.N., Kiebish, M.A., Marsh, J., Shelton, L.M., Huysentruyt, L.C., Mukherjee, P., Metabolic management of brain cancer. Biochim Biophys Acta 1807:6 (2011 Jun), 577–594.
80. [80] Zhou, W., Mukherjee, P., Kiebish, M.A., Markis, W.T., Mantis, J.G., Seyfried, T.N., The calorically restricted ketogenic diet, an effective alternative therapy for malignant brain cancer. Nutr Metab – Lond, 4, 2007 Feb 21, 5.
81. [81] Klein, S., Wolfe, R.R., Carbohydrate restriction regulates the adaptive response to fasting. Am J Physiol 262:5 Pt 1 (1992 May), E631–E636.
82. [82] Morris, A.A.M., Cerebral ketone body metabolism. J Inherit Metab Dis 28 (2005), 109–121.
83. [83] Cahill, G.F. Jr., Veech, R.L., Ketoacids? Good medicine?. Trans Am Clin Climatol Assoc 114 (2003), 149–161.
84. [84] Vanitallie, T.B., Nufert, T.H., Ketones: metabolism's ugly duckling. Nutr Rev 61 (2003), 327–341.
85. [85] Veech, R.L., Chance, B., Kashiwaya, Y., Lardy, H.A., Cahill, G.F., Ketone bodies, potential therapeutic uses. IUBMB Life 51 (2001), 241–247.
86. [86] Shimazu, T., Hirschey, M.D., Newman, J., He, W., Shirakawa, K., Le Moan, N., et al. Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 339 (2013), 211–214 95.
87. [87] Tisdale, M.J., Brennan, R.A., Fearon, K.C., Reduction of weight loss and tumour size in a cachexia model by a high fat diet. Br J Cancer 56:1 (1987 Jul), 39–43.
88. [88] Magee, B.A., Potezny, N., Rofe, A.M., Conyers, R.A., The inhibition of malignant cell growth by ketone bodies. Aust J Exp Biol Med Sci 57 (1979), 529–539.
89. [89] Scheck, A.C., Abdelwahab, M.G., Stafford, P., Kim, D.Y., Iwai, S., Preul, M.C., et al. Mechanistic studies of the ketogenic diet as an adjuvant therapy for malignant gliomas. Cancer Res 70:Suppl. 8 (2011), 1–10 638.
90. [90] Stafford, P., Abdelwahab, M.G., Kim, D.Y., Preul, M.C., Rho, J.M., Scheck, A.C., The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. Nutr Metab – Lond, 7, 2010, 74.
91. [91] Draznin, B., Wang, C., Adochio, R., Leitner, J.W., Cornier, M.A., Effect of dietary macronutrient composition on AMPK and SIRT1 expression and activity in human skeletal muscle. Horm Metab Res 44 (2012), 650–655.
92. [92] Bergouignan, A., Gozansky, W.S., Barry, D.W., Leitner, W., MacLean, P.S., Hill, J.O., et al. Increasing dietary fat elicits similar changes in fat oxidation and markers of muscle oxidative capacity in lean and obese humans. PLoS One, 7, 2012, e30164.
93. [93] Li, Y., Liu, L., Tollefsbol, T.O., Glucose restriction can extend normal cell lifespan and impair precancerous cell growth through epigenetic control of hTERT and p16 expression. FASEB J 24 (2010), 1442–1453.
94. [94] Demetrakopoulos, G.E., Brennan, M.F., Tumoricidal potential of nutritional manipulations. Cancer Res 42:Suppl. 2 (1982), 756s–765s.
95. [95] Beck, S.A., Tisdale, M.J., Effect of insulin on weight loss and tumour growth in a cachexia model. Br J Cancer 59 (1989), 677–681.
96. [96] Otto, C., Kaemmerer, U., Illert, B., Muehling, B., Pfetzer, N., Wittig, R., et al. Growth of human gastric cancer cells in nude mice is delayed by a ketogenic diet supplemented with omega-3 fatty acids and medium-chain triglycerides. BMC Cancer, 8, 2008 Apr 30, 122, 10.1186/1471-2407-8-122.
97. [97] Freedland, S.J., Mavropoulos, J., Wang, A., Darshan, M., Demark-Wahnefried, W., Aronson, W.J., et al. Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis. Prostate 68:1 (2008 Jan 1), 11–19.
98. [98] Urits, I., Mukherjee, P., Meidenbauer, J., Seyfried, T.N., Dietary restriction promotes vessel maturation in a mouse astrocytoma. J Oncol, 2012, 2012, 264039, 10.1155/2012/264039 [Epub 2011 Dec 27].
99. [99] Klement, R.J., Champ, C.E., Calories, carbohydrates, and cancer therapy with radiation: exploiting the five R's through dietary manipulation. Cancer Metastasis Rev 33 (2014 Jan 17), 217–229.
100. [100] Fine, E.J., Segal-Isaacson, C.J., Feinman, R.D., Herszkopf, S., Romano, M.C., Tomuta, N., et al. Targeting insulin inhibition as a metabolic therapy in advanced cancer: a pilot safety and feasibility dietary trial in 10 patients. Nutrition 28 (2012), 1028–1035.
101. [101] Kitada, M., Kume, S., Takeda-Watanabe, A., Tsuda, S., Kanasaki, K., Koya, D., Calorie restriction in overweight males ameliorates obesity-related metabolic alterations and cellular adaptations through anti-aging effects, possibly including AMPK and SIRT1 activation. Biochim Biophys Acta 1830:10 (2013; Oct), 4820–4827.
102. [102] Abdelwahab, M.G., Fenton, K.E., Preul, M.C., Rho, J.M., Lynch, A., Stafford, P., et al. The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma. PLoS One, 7(5), 2012, e36197.
103. [103] Johnson, J.B., John, S., Laub, D.R., Pretreatment with alternate day modified fast will permit higher dose and frequency of cancer chemotherapy and better cure rates. Med Hypotheses 72:4 (2009 Apr), 381–382.
104. [104] Cheng, C.W., Adams, G.B., Perin, L., Wei, M., Zhou, X., Lam, B.S., et al. Prolonged fasting reduces IGF-1/PKA to promote hematopoietic-stem-cell-based regeneration and reverse immunosuppression. Cell Stem Cell 14:6 (2014 Jun 5), 810–823.
105. [105] Derr, R.L., Ye, X., Islas, M.U., Desideri, S., Saudek, C.D., Grossman, S.A., Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma. J Clin Oncol 27:7 (2009 Mar 1), 1082–1086, 10.1200/JCO.2008.19.1098 [Epub 2009 Jan 12].
106. [106] McGirt, M.J., Chaichana, K.L., Gathinji, M., Attenello, F., Than, K., Ruiz, A.J., et al. Persistent outpatient hyperglycemia is independently associated with decreased survival after primary resection of malignant brain astrocytomas. Neurosurgery 63:2 (2008 Aug), 286–291.
107. [107] Chaichana, K.L., McGirt, M.J., Woodworth, G.F., Datoo, G., Tamargo, R.J., Weingart, J., et al. Persistent outpatient hyperglycemia is independently associated with survival, recurrence and malignant degeneration following surgery for hemispheric low grade gliomas. Neurol Res 32:4 (2010 May), 442–448.
108. [108] Kubicek, G.J., Champ, C., Fogh, S., Wang, F., Reddy, E., Intenzo, C., et al. FDG-PET staging and importance of lymph node SUV in head and neck cancer. Head Neck Oncol 2:19 (2010), 1–11.
109. [109] Chung, H.H., Kwon, H.W., Kang, K.W., Park, N.H., Song, Y.S., Chung, J.K., et al. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer. Ann Surg Oncol 19:6 (2012 Jun), 1966–1972.
110. [110] Saigusa, S., Toiyama, Y., Tanaka, K., Okugawa, Y., Fujikawa, H., Matsushita, K., et al. Prognostic significance of glucose transporter-1 (GLUT1) gene expression in rectal cancer after preoperative chemoradiotherapy. Surg Today 42:5 (2012 May), 460–469.
111. [111] August, D.A., Huhmann, M.B., American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors A.S.P.E.N. clinical guidelines: nutrition support therapy during adult anticancer treatment and in hematopoietic cell transplantation. J Parenter Enter Nutr 33:5 (2009 Sep–Oct), 472–500.
112. [112] Arends, J., Bodoky, G., Bozzetti, F., Fearon, K., Muscaritoli, M., Selga, G., et al. DGEM (German Society for Nutritional Medicine), ESPEN (European Society for Parenteral and Enteral Nutrition). ESPEN Guidelines on Enteral Nutrition: non-surgical oncology. Clin Nutr 25:2 (2006 Apr), 245–259 [Epub 2006 May 12].
113. [113] Bozzetti, F., Arends, J., Lundholm, K., Micklewright, A., Zurcher, G., Muscaritoli, M., ESPEN Guidelines on Parenteral Nutrition: non-surgical oncology. Clin Nutr 28:4 (2009; Aug), 445–454.
114. [114] Waterhouse, C., Kemperman, J.H., Carbohydrate metabolism in subjects with cancer. Cancer Res 31 (1971), 1273–1278.
115. [115] Legaspi, A., Jeevenandam, M., Fletcher Starnes, H. Jr., Brennan, M.F., Whole lipid and energy metabolism in the cancer patient. Metabolism 36 (1987), 958–963.
116. [116] Selberg, O., McMillan, D.C., Preston, T., Carse, H., Shenkin, A., Burns, H., et al. Palmitate turnover and its response to glucose infusion in weight-losing cancer patients. Clin Nutr 9 (1990), 150–156.
117. [117] Arbeit, M.A., Lees, D.A., Corsey, R., Brennan, M.F., Resting energy expenditure in controls and cancer patients with localized and diffuse disease. Ann Surg 199 (1984), 292–298.
118. [118] Shaw, J.F., Wolfe, R.R., Fatty acid and glycerol kinetics in septic patients and in patients with gastrointestinal cancer. Ann Surg 205 (1987), 368–376.
119. [119] Hansell, D.T., Davies, J.W.L., Burns, H.J.G., Shenkin, A., The oxidation of body fuel stores in cancer patients. Ann Surg 204 (1986), 638–642.
120. [120] Korber, J., Pricelius, S., Heidrich, M., Muller, M.J., Increased lipid utilization in weight-losing and weight-stable cancer patients with normal body weight. Eur J Clin Nutr 53 (1999), 740–745.
121. [121] Lindmark, L., Bennegård, K., Eden, E., Ternell, M., Svaninger, G., Lundholm, K., et al. Thermic effect and substrate oxidation in response to intravenous nutrition in cancer patients who lose weight. Ann Surg 204 (1986), 628–636.
122. [122] Lindmark, L., Bennegård, K., Eden, E., Ternell, M., Svaninger, G., Lundholm, K., Cancer cachexia: influence of systemic ketosis on substrate levels and nitrogen metabolism. Am J Clin Nutr 47 (1988), 42–48.
123. [123] Bozzetti, F., Gavazzi, C., Mariani, L., Crippa, E., Glucose-based total parenteral nutrition does not stimulate glucose uptake by human tumours. Clin Nutr 23 (2004), 417–421.
124. [124] Rossi-Fanelli, F., Franchi, F., Mulieri, M., Cangiano, C., Cascino, A., Ceci, F., et al. Effect of energy substrate manipulation on tumour cell proliferation in parenterally fed cancer patients. Clin Nutr 10:4 (1991 Aug), 228–232.
125. [125] Tayek, J.A., Heber, D., Chlebowski, R.T., Effect of hydrazine sulphate on whole-body protein breakdown measured by 14C-lysine metabolism in lung cancer patients. Lancet 2:8553 (1987 Aug 1), 241–244.
126. [126] Gold, J., Proposed treatment of cancer by inhibition of gluconeogenesis. Oncology 22:2 (1968), 185–207.
127. [127] Ray, P.D., Hanson, R.L., Lardy, H.A., Inhibition by hydrazine of gluconeogenesis in the rat. J Biol Chem 245:4 (1970 Feb 25), 690–696.
128. [128] Breitkreutz, R., Tesdal, K., Jentschura, D., Haas, O., Leweling, H., Holm, E., Effects of a high-fat diet on body composition in cancer patients receiving chemotherapy: a randomized controlled study. Wien Klin Wochenschr 117:19–20 (2005 Oct), 685–692.
129. [129] Nebeling, L.C., Miraldi, F., Shurin, S.B., Lerner, E., Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: two case reports. J Am Coll Nutr 14 (1995), 202–208.
130. [130] Bozzetti, F., Cozzaglio, L., Gavazzi, C., Brandi, S., Bonfanti, G., Lattarulo, M., et al. Total nutritional manipulation in humans: report of a cancer patient. Clin Nutr 15:4 (1996 Aug), 207–209.
131. [131] Safdie, F.M., Dorff, T., Quinn, D., Fontana, L., Wei, M., Lee, C., et al. Fasting and cancer treatment in humans: a case series report. Aging – Albany NY 1:12 (2009 Dec 31), 988–1007.
132. [132] Zuccoli, G., Marcello, N., Pisanello, A., Servadei, F., Vaccaro, S., Mukherjee, P., et al. Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: case report. Nutr Metab – Lond, 7, 2010 Apr 22, 33.
133. [133] Schmidt, M., Pfetzer, N., Schwab, M., Strauss, I., Kammerer, U., Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: a pilot trial. Nutr Metab – Lond, 8, 2011, 54.
134. [134] Champ, C.E., Palmer, J.D., Volek, J.S., Werner-Wasik, M., Andrews, D.W., Evans, J.J., et al. Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme. J Neurooncol 117:1 (2014 Mar), 125–131.
135. [135] Bozzetti, F., Mori, V., Nutritional support and tumour growth in humans: a narrative review of the literature. Clin Nutr 28:3 (2009 Jun), 226–230.
136. [136] Davis, M.P., Yavuzsen, T., Khoshknabi, D., Kirkova, J., Walsh, D., Lasheen, W., et al. Bioelectrical impedance phase angle changes during hydration and prognosis in advanced cancer. Am J Hosp Palliat Care 26:3 (2009), 180–187.
137. [137] Gupta, D., Lis, C.G., Dahlk, S.L., Vashi, P.G., Grutsch, J.F., Lammersfeld, C.A., Bioelectrical impedance phase angle as a prognostic indicator in advanced pancreatic cancer. Br J Nutr 92:6 (2004 Dec), 957–962.
138. [138] Gupta, D., Lammersfeld, C.A., Burrows, J.L., Dahlk, S.L., Vashi, P.G., Grutsch, J.F., et al. Bioelectrical impedance phase angle in clinical practice: implications for prognosis in advanced colorectal cancer. Am J Clin Nutr 80:6 (2004 Dec), 1634–1638.
139. [139] Gupta, D., Lammersfeld, C.A., Vashi, P.G., King, J., Dahlk, S.L., Grutsch, J.F., et al. Bioelectrical impedance phase angle as a prognostic indicator in breast cancer. BMC Cancer, 8, 2008 Aug 27, 249.
140. [140] Gupta, D., Lammersfeld, C.A., Vashi, P.G., King, J., Dahlk, S.L., Grutsch, J.F., et al. Bioelectrical impedance phase angle in clinical practice: implications for prognosis in stage IIIB and IV non-small cell lung cancer. BMC Cancer, 9, 2009 Jan 28, 37.
141. [141] Paiva, S.I., Borges, L.R., Halpern-Silveira, D., Assunção, M.C., Barros, A.J., Gonzalez, M.C., Standardized phase angle from bioelectrical impedance analysis as prognostic factor for survival in patients with cancer. Support Care Cancer 19:2 (2010 Feb), 187–192.
142. [142] Santarpia, L., Marra, M., Montagnese, C., Alfonsi, L., Pasanisi, F., Contaldo, F., Prognostic significance of bioelectrical impedance phase angle in advanced cancer: preliminary observations. Nutrition 25:9 (2009 Sep), 930–931.
143. [143] van Vledder, M.G., Levolger, S., Ayez, N., Verhoef, C., Tran, T.C., Ijzermans, J.N., Body composition and outcome in patients undergoing resection of colorectal liver metastases. Br J Surg 99:4 (2012 Apr), 550–557.
144. [144] Aslani, A., Smith, R.C., Allen, B.J., Paviakis, N., Levi, J.A., The predictive value of body protein for chemotherapy-induced toxicity. Cancer 88 (2000), 796–803.
145. [145] Prado, C.M., Baracos, V.E., McCargar, L.J., Reiman, T., Mourtzakis, M., Tonkin, K., et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 15:8 (2009 Apr 15), 2920–2926.
146. [146] Andreyev, H.J.N., Norman, A.R., Oates, J., Cunningham, D., Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?. Eur J Cancer 34:4 (1998), 503–509.
147. [147] Aviles, A., Yanez, J., López, T., Garcia, R., Guzmán, R., Díaz-Maqueo, J.C., et al. Malnutrition as an adverse prognostic factor in patients with diffuse large cell lymphoma. Arch Med Res 26 (1995), 31–34.
148. [148] Di Fiore, F., Lecleire, S., Pop, D., Rigal, O., Hamidou, H., Paillot, B., et al. Baseline nutritional status is predictive of response to treatment and survival in patients treated by definitive chemoradiotherapy for a locally advanced esophageal cancer. Am J Gastroenterol 102:11 (2007 Nov), 2557–2563.
149. [149] Mitry, E., Douillard, J.Y., Van Cutsem, E., Cunningham, D., Magherini, E., Mery-Mignard, D., et al. Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. Ann Oncol 15 (2004), 1013–1017.
150. [150] Ovesen, L., Allingstrup, L., Hannibal, J., Mortensen, E.L., Hansen, O.P., Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: a prospective, randomized study. J Clin Oncol 11:10 (1993 Oct), 2043–2049.
151. [151] Ross, P.J., Ashley, S., Norton, A., Priest, K., Waters, J.S., Eisen, T., et al. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?. Br J Cancer 90 (2004), 1905–1911.
152. [152] Van Eys, J., Effect of nutritional status on response to therapy. Cancer Res 42:Suppl. (1982), 747–753.
153. [153] Tubiana, M., Attié, E., Flamant, R., Gèrard-Marchant, R., Hayat, M., Prognostic factors in 454 cases of Hodgkin's disease. Cancer Res 31 (1971), 1801–1810.
154. [154] Swenerton, K.D., Legha, S.S., Smith, T., Hortobagyi, G.N., Gehan, E.A., Yap, H.Y., et al. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 39:5 (1979 May), 1552–1562.
155. [155] Feldman, S.A., Rubenstein, A.H., Ho, K.-J., Taylor, C.B., Lewis, L.A., Mikkelson, B., Carbohydrate and lipid metabolism in the Alaskan Arctic Eskimo. Am J Clin Nutr 28:6 (1975 Jun), 588–594.
156. [156] Ho, K.J., Mikkelson, B., Lewis, L.A., Feldman, S.A., Taylor, C.B., Alaskan Arctic Eskimo: responses to a customary high fat diet. Am J Clin Nutr 25:8 (1972 Aug), 737–745.
157. [157] Feldman, S.A., Ho, K.J., Lewis, L.A., Mikkelson, B., Taylor, C.B., Lipid and cholesterol metabolism in Alaskan Arctic Eskimos. Arch Pathol 94:1 (1972 Jul), 42–58.
158. [158] Bozzetti, F., Bozzetti, V., Is the intravenous supplementation of amino acid to cancer patients adequate? A critical appraisal of literature. Clin Nutr 32:1 (2013 Feb), 142–146.